Global Health Ltd
MEDANTA NSE
Global Health Ltd
Healthcare ServicesNSE: MEDANTA BSE: 543654 Hospitals
Key Fundamentals
SmallcapHospitalsHealthcare ServicesMarket Cap
₹38,171 Cr
Volatility
Moderate
P/E Ratio
69.73
EBITDA
₹918 Cr
Return on Equity
14.21%
Debt to Equity
0.3
Book Value
₹147.34
EPS
₹17.97
52W High
₹1,491
52W Low
₹956
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Global Health Ltd insights
39 extracted metrics + investor summaries across FY16–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company has delivered good profit growth of 80.7% CAGR over last 5 years
Weaknesses
1- Stock is trading at 9.60 times its book value
Growth Rate
Revenue Growth
16.94% ↗
Net Income Growth
21.29% ↗
Cash Flow Change
1.91% ↗
ROE
-13.62% ↘
ROCE
-9.67% ↘
EBITDA Margin (Avg.)
-19.68% ↘
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 5d agoAI opinion · based on fundamentals
Risk medium
Global Health Ltd (Medanta) is a hospital chain with a market cap of ₹38,125 crore trading at a P/E of 67.9x and 9.47x book value. FY2026 revenue grew ~19% YoY to ₹4,410 crore with consolidated PAT of ₹554 crore (up ~15% YoY), supported by an EBITDA margin of ~25.7%. The company is in an active expansion phase, planning to add ~2,800 beds over the next 4 years to its current ~3,579 bed capacity.
Bull Case 8
- Exceptional 5-year profit CAGR of 80.7%, reflecting strong operating leverage as hospitals mature
- FY2026 revenue grew 19.4% YoY to ₹4,410 crore, demonstrating sustained double-digit topline momentum
- EBITDA margin of 25.7% in FY2026 indicates strong operational efficiency for a multi-hospital chain
- 3-year compounded sales growth of 18% and TTM sales growth of 21% show consistent demand acceleration
- Planned capacity addition of ~2,800 beds (78% increase over current 3,579 beds) provides a long runway for revenue growth over 4 years
- Debt-to-equity ratio of 0.30x is manageable, providing balance sheet flexibility for expansion capex
- 3-year ROE averaging 16% reflects reasonable capital efficiency despite heavy expansion spending
- Q4 FY2026 PAT jumped 39.7% YoY to ₹141 crore, showing improving profitability trajectory in recent quarters
Bear Case 8
- P/E of 67.9x is significantly elevated versus the broader market, leaving limited margin of safety if growth slows
- Price-to-book of 9.47x implies heavy premium to net assets, making the stock vulnerable to de-rating
- TTM profit growth has decelerated to 0% compared to the 5-year CAGR of 81%, indicating possible near-term earnings plateau
- Dividend yield of just 0.04% offers negligible income return to shareholders at current valuation
- Aggressive bed expansion of 2,800 beds carries execution risk — new hospitals typically run at lower occupancy and margins for 2-3 years
- FY2025 revenue growth slowed to 12.7% YoY (vs 20.9% in FY2024), showing potential cyclical deceleration before FY2026 recovery
- 1-year stock CAGR of only 3% suggests the market has already priced in near-term growth, limiting easy upside
- ROE dipped to 15% in the last year from the 3-year average of 16%, reflecting dilution of returns as capital is deployed into greenfield projects
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 20h ago Headwinds 1
- Q1FY27 profit declines Jul 30
Global Health reported Q1FY27 standalone PAT of ₹1,373.07 million, marking a dip from prior period. Profit decline signals potential margin pressure in the quarter ended June 2026.
Positives 2
- ₹970 crore Guwahati expansion approved Jul 30
Board approved ₹970 crore expansion of Guwahati hospital to 650 beds, signaling aggressive capacity addition in the Northeast region.
- ESOP grant signals talent retention Jul 30
Nomination and Remuneration Committee granted 20,000 stock options at ₹1,147 exercise price under GHL LTIP 2024 Plan, aimed at retaining key talent.
Neutral 2
- Q1 FY27 earnings call scheduled Jul 25
Conference call set for July 31, 2026, hosted by JM Financial, to discuss Q1 FY27 results for the quarter ended June 30, 2026.
- New CDO appointment Jul 30
Pradeep Kumar Singh appointed as Chief Digital Officer, strengthening the leadership team alongside the quarterly results announcement.
TL;DR: Global Health is investing aggressively in capacity expansion with the ₹970 crore Guwahati project, but Q1FY27 profit has dipped, raising near-term margin concerns. The company is strengthening leadership and retention through new appointments and ESOPs. The long-term growth trajectory looks intact via bed additions, though investors should watch whether profitability recovers in coming quarters as expansion costs flow through.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 780 | 844 | 836 | 809 | 861 | 957 | 943 | 931 | 1,031 | 1,099 | 1,121 | 1,159 | 1,304 |
| Expenses | 595 | 631 | 620 | 629 | 675 | 728 | 706 | 707 | 784 | 868 | 904 | 915 | 1,017 |
| Operating Profit | 184 | 213 | 216 | 179 | 186 | 228 | 238 | 225 | 247 | 231 | 217 | 244 | 287 |
| OPM % | 24% | 25% | 26% | 22% | 22% | 24% | 25% | 24% | 24% | 21% | 19% | 21% | 22% |
| Other Income | 15 | 21 | 18 | 27 | 22 | 18 | 16 | -27 | 20 | 36 | -15 | 37 | 22 |
| Interest | 18 | 20 | 18 | 18 | 18 | 16 | 16 | 15 | 14 | 17 | 22 | 27 | 27 |
| Depreciation | 40 | 43 | 44 | 45 | 47 | 49 | 48 | 49 | 45 | 50 | 61 | 67 | 69 |
| PBT | 141 | 171 | 172 | 143 | 144 | 181 | 189 | 133 | 208 | 200 | 120 | 187 | 213 |
| Tax % | 28% | 27% | 28% | 11% | 26% | 28% | 24% | 24% | 24% | 21% | 21% | 24% | 26% |
| Net Profit | 102 | 125 | 124 | 127 | 106 | 131 | 143 | 101 | 159 | 158 | 95 | 142 | 157 |
| EPS in Rs | 3.8 | 4.66 | 4.61 | 4.74 | 3.96 | 4.87 | 5.32 | 3.78 | 5.92 | 5.89 | 3.54 | 5.36 | 5.9 |
Profit & Loss
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,382 | 1,343 | 1,456 | 1,500 | 1,447 | 2,167 | 2,710 | 3,275 | 3,692 | 4,410 | 4,683 |
| Expenses | 1,081 | 1,218 | 1,283 | 1,309 | 1,250 | 1,709 | 2,073 | 2,466 | 2,806 | 3,491 | 3,705 |
| Operating Profit | 301 | 125 | 172 | 192 | 197 | 458 | 637 | 809 | 886 | 919 | 979 |
| OPM % | 22% | 9% | 12% | 13% | 14% | 21% | 24% | 25% | 24% | 21% | 21% |
| Other Income | 45 | 49 | 50 | 44 | 31 | 39 | 49 | 75 | 29 | 98 | 80 |
| Interest | 14 | 28 | 38 | 57 | 73 | 86 | 86 | 84 | 74 | 79 | 92 |
| Depreciation | 70 | 86 | 102 | 115 | 123 | 130 | 150 | 173 | 194 | 223 | 246 |
| PBT | 262 | 60 | 83 | 64 | 32 | 281 | 449 | 627 | 647 | 715 | 720 |
| Tax % | 35% | 45% | 38% | 43% | 11% | 30% | 27% | 24% | 26% | 23% | — |
| Net Profit | 170 | 33 | 51 | 36 | 29 | 196 | 326 | 478 | 481 | 554 | 552 |
| EPS in Rs | 35.1 | 6.78 | 10.44 | 7.36 | 5.81 | 7.75 | 12.16 | 17.81 | 17.92 | 20.7 | 20.69 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 48 | 48 | 49 | 49 | 50 | 51 | 54 | 54 | 54 | 54 |
| Reserves | 976 | 1,136 | 1,246 | 1,300 | 1,333 | 1,565 | 2,375 | 2,852 | 3,333 | 3,908 |
| Borrowings | 165 | 456 | 787 | 929 | 931 | 1,109 | 1,122 | 802 | 718 | 1,190 |
| Other Liabilities | 295 | 343 | 347 | 388 | 380 | 421 | 547 | 572 | 662 | 753 |
| Total Liabilities | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,905 |
| Fixed Assets | 914 | 1,094 | 1,194 | 1,703 | 1,616 | 1,776 | 2,050 | 2,236 | 2,514 | 3,795 |
| CWIP | 12 | 317 | 666 | 382 | 464 | 439 | 327 | 388 | 533 | 132 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Other Assets | 559 | 573 | 570 | 581 | 615 | 930 | 1,720 | 1,656 | 1,716 | 1,975 |
| Total Assets | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,905 |
Cash Flow
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 228 | 63 | 166 | 175 | 242 | 311 | 645 | 612 | 624 | 714 |
| Investing | -241 | -69 | -249 | -87 | -239 | -421 | -342 | -441 | -721 | -1,089 |
| Financing | -7 | 9 | 97 | -1 | -81 | 160 | 346 | -514 | -97 | 272 |
| Net Cash Flow | -20 | 3 | 14 | 87 | -78 | 50 | 648 | -343 | -194 | -103 |
| Free Cash Flow | 71 | -81 | -133 | -13 | 100 | 38 | 409 | 335 | 110 | -263 |
| CFO/OP | 108 | 93 | 135 | 121 | 131 | 89 | 118 | 98 | 89 | 91 |
Ratios
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 20 | 41 | 41 | 36 | 34 | 30 | 26 | 24 | 29 | 34 |
| Inventory Days | 28 | 26 | 26 | 43 | 42 | 36 | 35 | 32 | 28 | 29 |
| Days Payable | 92 | 124 | 142 | 147 | 138 | 90 | 114 | 90 | 81 | 89 |
| Cash Conversion Cycle | -45 | -56 | -75 | -67 | -62 | -24 | -52 | -34 | -24 | -26 |
| Working Capital Days | -23 | -33 | -18 | -31 | -48 | -20 | -37 | -32 | -21 | -7 |
| ROCE % | — | — | 6% | 6% | 5% | 15% | 17% | 20% | 20% | 17% |
Documents
1
Announcement under Regulation 30 (LODR)-Meeting Updates
15h - Global Health granted 10,000 ESOPs to one employee under GHL LTIP 2024 on May 11, 2026. 15h - Global Health granted 10,000 ESOPs to one employee under GHL LTIP 2024 on May 11, 2026.
2
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8h - Medanta schedules Q4 FY2026 earnings conference call on May 15, 2026 at 2:00 PM IST, hosted by ICICI Securities. 8h - Medanta schedules Q4 FY2026 earnings conference call on May 15, 2026 at 2:00 PM IST, hosted by ICICI Securities.
3
Board Meeting Intimation for Approval Of Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026 And Recommendation Of Final Dividend.
6 May - Board meets May 14, 2026 to approve FY26 audited results and consider final dividend. 6 May - Board meets May 14, 2026 to approve FY26 audited results and consider final dividend.
4
Announcement under Regulation 30 (LODR)-Acquisition
27 Apr - Approved BTA to acquire 79-bed cancer hospital in Indore for Rs 30 crore, adding capacity. 27 Apr - Approved BTA to acquire 79-bed cancer hospital in Indore for Rs 30 crore, adding capacity.
5
Announcement under Regulation 30 (LODR)-Meeting Updates
27 Apr - Board approved BTA for 79-bed Indore cancer hospital acquisition for Rs 30 crore; completion by September 30, 2026. 27 Apr - Board approved BTA for 79-bed Indore cancer hospital acquisition for Rs 30 crore; completion by September 30, 2026.
Frequently Asked Questions about Global Health Ltd
What does Global Health Ltd do?
Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transp...
Where is Global Health Ltd (MEDANTA) listed?
Global Health Ltd is listed on the Indian stock exchanges. It is listed on NSE: MEDANTA and BSE: 543654. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Global Health Ltd belong to?
Global Health Ltd operates in the Healthcare Services sector within the Hospitals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Global Health Ltd?
Global Health Ltd has a market capitalisation of approximately ₹38171.16 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Global Health Ltd?
The Price-to-Earnings (PE) ratio of Global Health Ltd is 69.73. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Global Health Ltd?
Over the past 52 weeks, Global Health Ltd has traded between a low of ₹956 and a high of ₹1,491. This range helps investors understand the stock's price volatility and recent trading levels.
Does Global Health Ltd pay dividends?
Yes, Global Health Ltd has a dividend yield of 0.04%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Global Health Ltd?
Global Health Ltd has a Return on Equity (ROE) of 14.21%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Global Health Ltd on Tapetide?
On Tapetide, you can view Global Health Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology.[1]